BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RDEA594: Preliminary Phase IIb data

Top-line data from a double-blind Phase IIb trial in 208 patients showed that once-daily 200, 400 and 600 mg oral RDEA594 plus allopurinol met the primary endpoint of significantly reducing mean sUA levels from baseline to week 4 vs. placebo plus allopurinol (16%,...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >